Peter Bang

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

P. Andersen, R. Shattock, K. Korsholm, 2019, The Lancet. Infectious diseases.

Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.

K. Stagliano, P. Andersen, J. Sadoff, 2010, Vaccine.

Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis.

Courtney R. Plumlee, D. Sherman, A. Sette, 2017, Cell host & microbe.

Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.

B. Mordmüller, P. Kremsner, S. Sirima, 2021, Vaccine.

A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.

M. Christiansen, B. Mordmüller, S. Issifou, 2016, Vaccine.

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.

T. Ottenhoff, T. Ottenhoff, P. Andersen, 2011, Vaccine.